Stockscreener 앱 받기
24.21
3.59%
0.84
시간 외 거래:
24.21
전일 마감가:
$23.37
열려 있는:
$23.52
하루 거래량:
172.32K
Relative Volume:
0.58
시가총액:
$612.49M
수익:
-
순이익/손실:
$-61.59M
주가수익비율:
-8.8798
EPS:
-2.7264
순현금흐름:
-
1주 성능:
+1.89%
1개월 성능:
-3.70%
6개월 성능:
+61.94%
1년 성능:
+0.00%
1일 변동 폭
$22.84
$24.59
1주일 범위
$22.48
$24.59
52주 변동 폭
$13.36
$27.55
Lb Pharmaceuticals Inc Stock (LBRX) Company Profile
명칭
Lb Pharmaceuticals Inc
전화
917-450-6581
주소
575 MADISON AVENUE, NEW YORK
Compare LBRX vs VRTX, REGN, ALNY, ARGX, INSM
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
LBRX
Lb Pharmaceuticals Inc
|
24.21 | 591.24M | 0 | -61.59M | 0 | -2.7264 |
VRTX
Vertex Pharmaceuticals Inc
|
454.97 | 113.96B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
749.47 | 78.41B | 14.34B | 4.50B | 3.77B | 41.56 |
ALNY
Alnylam Pharmaceuticals Inc
|
328.70 | 40.85B | 3.71B | 313.75M | 465.38M | 2.2571 |
ARGX
Argen X Se Adr
|
697.05 | 42.05B | 4.16B | 1.29B | 734.26M | 19.58 |
INSM
Insmed Inc
|
148.31 | 29.99B | 606.42M | -1.28B | -997.58M | -6.403 |
Lb Pharmaceuticals Inc Stock (LBRX) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2026-01-09 | 개시 | Roth Capital | Buy |
| 2025-10-06 | 개시 | Leerink Partners | Outperform |
| 2025-10-06 | 개시 | Piper Sandler | Overweight |
| 2025-10-06 | 개시 | Stifel | Buy |
Lb Pharmaceuticals Inc 주식(LBRX)의 최신 뉴스
LB Pharmaceuticals starts phase 3 trial for schizophrenia drug - Investing.com
LB Pharmaceuticals initiates pivotal phase 3 trial (Nova-2) for LB-102 in patients with schizophrenia - marketscreener.com
LB Pharmaceuticals Initiates Pivotal Phase 3 Trial (NOVA-2) for LB-102 in Patients with Schizophrenia - Yahoo Finance Singapore
LB Pharmaceuticals Inc(NasdaqGM: LBRX) added to S&P Global BMI Index - marketscreener.com
LB Pharmaceuticals Inc(NasdaqGM:LBRX) added to S&P Pharmaceuticals Select Industry Index - marketscreener.com
LB Pharmaceuticals CEO Maps LB-102 Milestones, Says Pipeline Fully Funded Into Q2 2029 - MarketBeat
LBRX: LB-102 advances toward pivotal data in major CNS indications, fully funded through 2029 - TradingView
LB Pharmaceuticals (NASDAQ:LBRX) Stock Price Down 4.6%Should You Sell? - MarketBeat
LB Pharmaceuticals director Zachary Prensky to retire after 2026 annual meeting - Investing.com India
LB Pharmaceuticals director Zachary Prensky to retire after 2026 annual meeting By Investing.com - Investing.com South Africa
LB Pharmaceuticals Announces Director Zachary Prensky’s Planned Retirement - TipRanks
LB Pharmaceuticals (NASDAQ: LBRX) director to retire and serve as consultant - Stock Titan
Boxer Capital Management LLC Acquires Shares of 70,000 LB Pharmaceuticals Inc $LBRX - MarketBeat
Commodore Capital LP Invests $23.69 Million in LB Pharmaceuticals Inc $LBRX - MarketBeat
200,000 Shares in LB Pharmaceuticals Inc $LBRX Bought by Baker BROS. Advisors LP - MarketBeat
300,000 Shares in LB Pharmaceuticals Inc $LBRX Acquired by Nan Fung Group Holdings Ltd - MarketBeat
100,000 Shares in LB Pharmaceuticals Inc $LBRX Purchased by Integral Health Asset Management LLC - MarketBeat
LB Pharmaceuticals appoints Robert Lenz to board of directors By Investing.com - Investing.com Nigeria
LB Pharmaceuticals (NASDAQ:LBRX) Sets New 12-Month HighShould You Buy? - MarketBeat
Bipolar Depression Market Expected to Witness Accelerated Expansion During the Forecast Period (2026-2036) Amid Advancements in Psychiatric Therapies | DelveInsight - The Malaysian Reserve
LB Pharmaceuticals (LBRX) director receives 20,000 stock options vesting 2027–2029 - Stock Titan
LB Pharmaceuticals (LBRX) director Robert Lenz files initial Form 3 - Stock Titan
LB Pharmaceuticals adds neuroscience leader to board, governance - TipRanks
LB Pharmaceuticals (Nasdaq: LBRX) names new director and COO - Stock Titan
LB Pharmaceuticals Inc Approves the Promotion of Gad Soffer, the Chief Business Officer, to the Position of Chief Operating and Business Officer, Effective March 4, 2026 - marketscreener.com
Certain Stock Options of LB Pharmaceuticals Inc are subject to a Lock-Up Agreement Ending on 10-MAR-2026. - marketscreener.com
3,433,470 Common Stock of LB Pharmaceuticals Inc are subject to a Lock-Up Agreement Ending on 10-MAR-2026. - marketscreener.com
LB Pharmaceuticals appoints Robert Lenz to board of directors - Investing.com
LB Pharmaceuticals Appoints R&D Biotech Executive Robert Lenz, M.D., Ph.D. to Board of Directors - Bitget
LB Pharmaceuticals Inc (NASDAQ:LBRX) Given Consensus Recommendation of "Moderate Buy" by Brokerages - MarketBeat
LB Pharmaceuticals Inc (LBRX) Dividend News Alerts - DividendInvestor.com
LB Pharmaceuticals Inc’s Lock-Up Period Will Expire on March 10th (NASDAQ:LBRX) - Defense World
LB Pharmaceuticals to Participate in Upcoming March Investor Events - Bitget
LBRX SEC FilingsLB Pharmaceuticals 10-K, 10-Q, 8-K Forms - Stock Titan
LB Pharmaceuticals (NASDAQ:LBRX) Sets New 52-Week HighTime to Buy? - MarketBeat
JPMorgan Chase & Co. Buys Shares of 1,032,603 LB Pharmaceuticals Inc $LBRX - MarketBeat
LB Pharmaceuticals Inc's (NASDAQ:LBRX) Lock-Up Period Set To End on March 10th - MarketBeat
LB Pharmaceuticals Inc’s (NASDAQ:LBRX) Lock-Up Period Set To End on March 10th - Defense World
LBRX Technical Analysis & Stock Price Forecast - Intellectia AI
Psychedelic Biotechs Push Toward Phase 3: Five Companies Advancing CNS Treatments - marketscreener.com
Analysts Conflicted on These Healthcare Names: Merit Medical Systems (MMSI), LB Pharmaceuticals, Inc. (LBRX) and Cytokinetics (CYTK) - The Globe and Mail
LB Pharmaceuticals Inc (NASDAQ:LBRX) Receives Consensus Rating of "Moderate Buy" from Brokerages - MarketBeat
LB Pharmaceuticals Inc (NASDAQ:LBRX) Receives Consensus Rating of “Moderate Buy” from Brokerages - Defense World
Eton Pharmaceuticals, Inc. (NASDAQ:ETON) Given Average Rating of “Hold” by Analysts - Defense World
LB Pharmaceuticals Reports Inducement Grant to New Employee Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times
Neuro drug developer LB Pharma seeks $300M+ valuation in U.S. IPO - MSN
Lb Pharmaceuticals Inc (LBRX) 재무 분석
매출
순이익
현금흐름
주당 순 이익
1.82%
자본화:
|
볼륨(24시간):